Related Experiment Video

Updated: Jul 12, 2026

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)
08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)

Published on: January 7, 2018

Frequency of hypoglycaemia during the intravenous glucose tolerance test in overweight children

Martha L Cruz1, Marc J Weigensberg, Richard N Bergman

  • 1Department of Health Promotion, College of Health Sciences, University of Texas at El Paso, El Paso, TX 79902, USA. mcruz4@utep.edu

International Journal of Pediatric Obesity : IJPO : an Official Journal of the International Association for the Study of Obesity
|September 1, 2007
PubMed

Insights

Hypoglycaemia is rare during the insulin-modified, frequently sampled intravenous glucose tolerance test (FSIVGTT) in overweight Hispanic children. This diabetes risk study found very few participants experienced low blood glucose levels.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Research
  • Diabetes Risk Assessment

Background:

  • Overweight and obesity in Hispanic children are significant risk factors for type 2 diabetes.
  • Understanding glucose metabolism and insulin sensitivity is crucial for early risk identification.

Purpose of the Study:

  • To determine the incidence of hypoglycemia during an insulin-modified frequently sampled intravenous glucose tolerance test (FSIVGTT).
  • To assess the safety and feasibility of the FSIVGTT in overweight Hispanic youth as part of type 2 diabetes risk research.

Main Methods:

  • The study involved 210 overweight Hispanic children (mean age 11 years).
  • Participants underwent an insulin-modified FSIVGTT with intravenous glucose and insulin administration.
  • Plasma glucose and insulin levels were measured over 180 minutes to assess insulin sensitivity.

Main Results:

  • Hypoglycemia (plasma glucose <50 mg/dL) was observed in only one asymptomatic child (<0.5%).
  • A total of 1.9% of subjects (n=4) had plasma glucose <60 mg/dL at any point during the test.
  • The insulin-modified FSIVGTT demonstrated a very low frequency of hypoglycemia in this cohort.

Conclusions:

  • The insulin-modified FSIVGTT is a safe procedure with a very low risk of hypoglycemia in overweight Hispanic children.
  • This method is suitable for evaluating insulin sensitivity and glucose metabolism in youth at risk for type 2 diabetes.

More Related Videos

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test06:59

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

Published on: November 13, 2016

Improving IV Insulin Administration in a Community Hospital12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...